Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Heart Failure, Diastolic 1Breast Neoplasms 1

Interventions

Capecitabine 17Paclitaxel 16Docetaxel 13Carboplatin 12Cyclophosphamide 11Gemcitabine 9Epirubicin 9Trastuzumab 8Letrozole 8Doxorubicin 7pertuzumab 5Cisplatin 5Vinorelbine 4130-nm albumin-bound paclitaxel 4exemestane 3Zoledronic Acid 3Tamoxifen 3Neoadjuvant Therapy 3Lapatinib 3Injections 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3pyrotinib 2palbociclib 2camrelizumab 2apatinib 2Thiotepa 2Taxes 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Eplerenone × Breast × Clear all
NCT01708798 2017-01-05

Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer

University of British Columbia

Phase 2/3 Terminated
44 enrolled
Breast

Breast Neoplasms, Heart Failure, Diastolic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡